Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of CYP2C91/3 and 1/13 on the pharmacokinetics of losartan and its active metabolite E-3174.

International journal of clinical pharmacology and therapeutics - 1 Sept 2012

Bae Jung-Woo, Choi Chang-Ik, Lee Hye-In, Lee Yun-Jeong, Jang Choon-Gon, Lee Seok-Yong

Abstract excerpt

OBJECTIVE: The effects of CYP2C9*1/*3 and *1/*13 genotypes were evaluated on the pharmacokinetics of losartan and its active metabolite, E-3174, in Korean subjects. METHODS: Losartan (50 mg) was administered in 43 Korean volunteers with different CYP2C9 genotypes (CYP2C9*1/*1, *1/*3 and *1/*13). Losartan and E-3174 levels in the plasma and urine were analyzed by HPLC using fluorescence. RESULTS: The CYP2C9*1/*13...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Angiotensin II Type 1 Receptor Blockers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biotransformation

Share to Cytochrome P-450 CYP2C9

Share to Half-Life

Share to Losartan

Share to Metabolic Clearance Rate

Share to Tetrazoles

Source

Identifiers

PMID: 22735459
DOI: 10.5414/CP201467

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.PMID 22735459Read ↗

Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.Semantic proximity Read ↗

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.Semantic proximity Read ↗

Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.Semantic proximity Read ↗

CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.Semantic proximity Read ↗

Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.Semantic proximity Read ↗

Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.Semantic proximity Read ↗

Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.Semantic proximity Read ↗

Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects.Semantic proximity Read ↗

Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects.Semantic proximity Read ↗

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.Semantic proximity Read ↗

Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.Semantic proximity Read ↗

[Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.